Vitura Health Limited VIT

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methylenedioxymethamphetamine). Cortexa is a 50/50 joint venture between PharmAla Biotech (CSE: MDMA) and Vitura Health (ASX: VIT). Following completion of the world’s largest (and first Australian) GMP batch of MDMA capsules earlier this financial year, the Company has secured supply arrangements with a